SCHEMBL22505053

SCHEMBL22505053

CC(O)c1oc(=O)c2ccccc2c1-c1ccc(Cl)c(C2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ MAOB P27338 1/20 0.33
▸ LMNA P02545 1/20 0.32
▸ PPARG P37231 1/20 0.32
▸ NCOA2 Q15596 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ RXFP1 Q9HBX9 1/20 0.32
▸ NCOR2 Q9Y618 1/20 0.32
▸ TP53 P04637 2/20 0.32
▸ TNKS O95271 1/20 0.31
▸ PARP1 P09874 1/20 0.31
▸ TNKS2 Q9H2K2 1/20 0.31
▸ HDAC6 Q9UBN7 1/20 0.31
▸ PARP2 Q9UGN5 1/20 0.31
▸ ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22498233 0.90 MEN1 (0.32) MEN1ALDH1A1GAAKMT2ASMN1; SMN2
SCHEMBL29641596 0.90 MEN1 (0.32) MEN1ALDH1A1GAAKMT2ASMN1; SMN2
SCHEMBL22498297 0.88 TP53 (0.36) MEN1ALDH1A1GAAKMT2ASMN1; SMN2
SCHEMBL16783859 0.82 ALDH1A1 (0.40) MEN1ALDH1A1GAAKMT2ASMN1; SMN2
SCHEMBL16783636 0.82 HPGD (0.34) MEN1ALDH1A1GAAKMT2ASMN1; SMN2
SCHEMBL22505055 0.78 PIK3CD (0.40) —
SCHEMBL22504995 0.77 TP53 (0.34) MEN1ALDH1A1GAAKMT2ASMN1; SMN2
SCHEMBL29641568 0.77 TP53 (0.34) MEN1ALDH1A1GAAKMT2ASMN1; SMN2
SCHEMBL22498294 0.77 ALDH1A1 (0.34) MEN1ALDH1A1GAAKMT2ASMN1; SMN2
SCHEMBL22498300 0.77 PIK3CD (0.40) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12527797-B2 Isochromene derivatives as phosphoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-01-20 — — US disclosed
EP-3947384-B1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2023-11-01 — — EP disclosed
EP-3947384-B1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2023-11-01 — — EP disclosed
US-20220175784-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-09 — — US disclosed
US-20220175784-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-09 — — US disclosed
EP-3947384-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2022-02-09 — — EP disclosed
WO-2020200918-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-10-08 — — WO disclosed
WO-2020200918-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220175784-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS PIKFYVE, PDPK1, PIK3R5 MEN1 2896/4885ALDH1A1 3562/4885GAA 1329/4885
US-12527797-B2 Isochromene derivatives as phosphoinositide 3-kinases inhibitors PIK3R5, PIK3CD, PIK3R4 MEN1 3879/4885ALDH1A1 3567/4885GAA 3918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback